TISIDB

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF00170 bZIP transcription factor
Function	-

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001701 in utero embryonic development GO:0001890 placenta development GO:0006352 DNA-templated transcription, initiation GO:0006968 cellular defense response GO:0006979 response to oxidative stress GO:0007028 cytoplasm organization GO:0007292 female gamete generation GO:0007296 vitellogenesis GO:0007565 female pregnancy GO:0007611 learning or memory GO:0007612 learning GO:0009612 response to mechanical stimulus GO:0009615 response to virus GO:0009629 response to gravity GO:0009991 response to extracellular stimulus GO:0010035 response to inorganic substance GO:0014074 response to purine-containing compound GO:0022412 cellular process involved in reproduction in multicellular organism GO:0031334 positive regulation of protein complex assembly GO:0031668 cellular response to extracellular stimulus GO:0031960 response to corticosteroid GO:0032570 response to progesterone GO:0042493 response to drug GO:0042542 response to hydrogen peroxide GO:0043254 regulation of protein complex assembly GO:0044089 positive regulation of cellular component biogenesis GO:0044706 multi-multicellular organism process GO:0044708 single-organism behavior GO:0045787 positive regulation of cell cycle GO:0046683 response to organophosphorus GO:0048545 response to steroid hormone GO:0048608 reproductive structure development GO:0050890 cognition GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051384 response to glucocorticoid GO:0051385 response to mineralocorticoid GO:0051412 response to corticosterone GO:0051591 response to cAMP GO:0060674 placenta blood vessel development GO:0061458 reproductive system development GO:0061614 pri-miRNA transcription from RNA polymerase II promoter GO:0071496 cellular response to external stimulus GO:1901654 response to ketone GO:2000142 regulation of DNA-templated transcription, initiation GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component	GO:0042734 presynaptic membrane GO:0097060 synaptic membrane GO:0098793 presynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04310 Wnt signaling pathway hsa04380 Osteoclast differentiation
Reactome	-

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FOSL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FOSL1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
20386569	Breast Carcinoma	Inhibit immunity	Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. The 4T1 cells stimulate de novo overexpression of Fra-1 in RAW264.7 cells, and then Fra-1 binds to the interleukin 6 (IL-6) promoter to increase the production of the cytokine IL-6 in RAW264.7 cells.

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FOSL1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FOSL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.705	0.317
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.613	0.745
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.744	0.512
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.73	0.23
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.894	0.584
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.518	0.806
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.313	0.662
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.668	0.562
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.201	0.862
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.765	0.403
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.075	0.372
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.498	0.0147

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FOSL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOSL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOSL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOSL1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOSL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FOSL1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FOSL1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FOSL1
Name	FOS-like antigen 1
Aliases	fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FOSL1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FOSL1